Abstract

A NOVEL SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT) INHIBITOR CANAGLIFLOGIN

ABSTRACT

A vast majority of cases of diabetes fall into two broad aetiopathgenetic categories – type 1 and type 2 diabetes. The primary aim of management of type 2 diabetes is to achieve recommended levels of glucose control and thereby delay the potentially life threatening microvascular complications. It is not only challenging, but problematic to achieve and maintain optimum glycaemic control with the currently available treatment options. In addition, some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Increased knowledge of the pathophysiology of diabetes has contributed to the development of novel treatments. The most recent example of such novel medication belongs to the category of sodium glucose co-transporter 2 (SGLT) inhibitors. SGLT2 inhibitors have been a focus of clinical research in the management of type 2 diabetes over the past two decades. Dapagliflozin (ForxigaTM) and Canagliflozin (INVOKANATM) are the two important drugs from this novel category. The U.S. Food and Drug Administration recently approved canagliflozin tablets, used with diet and exercise, to improve glycemic control in adults with type 2 diabetes.

Keywords: Type 2 diabetes, Canagliflozin, SGLT2 inhibitors.